Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 128

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 128
---
 therein, and the offering of such securities at that time shall 
 be deemed to be the initial bona fide offering thereof                                                                                |

<div align='center'>II-5

SIGNATURES</div>

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement on Form F-3 to be signed on its behalf by the undersigned, thereunto duly authorized, in Zurich, Switzerland on February 4, 2025.

| NLS Pharmaceutics Ltd. |                     |
| By:                    | /s/ Alexander Zwyer |
|                        | Alexander Zwyer     |
|                        | Chief               
 Executive Officer   
 (Principal          
 Executive Officer)  |

<div align='center'>POWER OF ATTORNEY</div>

The undersigned officers and directors of NLS Pharmaceutics Ltd. hereby constitute and appoint Alexander Zwyer with full power of substitution, as our true and lawful attorney-in-fact and agent to take any actions to enable the Company to comply with the Securities Act, and any rules, regulations and requirements of the SEC, in connection with this registration statement on Form F-3, including the power and authority to sign for us in our names in the capacities indicated below any and all further amendments to this registration statement and any other registration statement filed pursuant to the provisions of Rule 462 under the Securities Act.

Pursuant to the requirements of the Securities Act, this registration statement on Form F-3 has been signed by the following persons in the capacities and on the dates indicated.

| Signature                         
 /s/ Alexander Zwyer               |     | Title                                               
 Chief Executive Officer and Director                |     | Date             
 February 4, 2025 |
|:----------------------------------|:----|:----------------------------------------------------|:----|:-----------------|
| Alexander Zwyer                   |     | -Principal Executive Officer                        |     |                  |
| /s/ Nicole Fernandez–McGovern     |     | Chief Financial Officer and Chief Operating Officer |     | February 4,      
 2025             |
| Nicole Fernandez–McGovern         |     | -Principal Financial and Accounting Officer         |     |                  |
| /s/ Ronald Hafner                 |     | Chairman of the Board of Directors                  |     | February 4, 2025 |
| Ronald Hafner                     |     |                                                     |